The beneficial effect of icaritin on osteoporotic bone is dependent on the treatment initiation timing in adult ovariectomized rats
- PMID: 23486180
- DOI: 10.1016/j.bone.2013.02.012
The beneficial effect of icaritin on osteoporotic bone is dependent on the treatment initiation timing in adult ovariectomized rats
Abstract
Background: Epimedium-derived flavonoids (EFs) have a potential to treat established osteoporosis in postmenopausal women. However, one of the main disadvantages of the compound is the high volume and dosage during long-term administration period. Meanwhile, the beneficial effect of EFs on osteoporotic bone depends greatly on the intervention timing. Whether icaritin (ICT), an active molecular compound from EFs, can exert beneficial effect on osteoporotic bone and whether the beneficial effect is also dependent on the intervention timing remain unknown.
Objective: The objective of this study was to evaluate the effect of the early and late ICT treatment on bone turnover markers, trabecular architecture, bone remodeling, biomechanics, colony formation of bone marrow stromal cells and osteoblast, adipocyte and osteoclast-related gene expression in adult ovariectomized rats.
Methods: Eighty 9-month-old female rats (n=8/group) were sham-operated (Sham) or ovariectomized (OVX). The OVX rats were subjected to ICT treatment initiation at 1 month (early treatment) and 3 months (late treatment) post-operation, respectively. The vehicle-treated Sham and OVX rats starting at month 1 and month 3 post-operation served as the corresponding controls (Sham and OVX controls) for early and late ICT treatment, respectively. Those Sham and OVX rats sacrificed immediately before early and late ICT treatment served as the pretreatment baseline controls. Both ICT and vehicle treatments lasted for 2 months. The bone turnover markers, trabecular architecture, bone remodeling and bone biomechanical properties were analyzed with biochemistry, microCT, histomorphometry and mechanical testing, respectively. The population of bone marrow stromal cells (BMSCs) and osteoblasts were evaluated with colony formation assays, respectively. The expression levels of osteoblast, adipocyte and osteoclast-related genes in bone marrow were assessed by real-time polymerase chain reaction (PCR), respectively.
Results: At the tissue level, early ICT treatment remarkably restored the trabecular bone mass, trabecular architecture and bone biomechanical properties towards pretreatment Sham levels, and significantly increased bone formation from pretreatment OVX level and markedly inhibited bone resorption towards pretreatment Sham level, whereas late ICT treatment failed to have any effect. At the cellular and molecular level, early ICT treatment significantly increased the number of osteoblastic colonies and the level of osteoblast-related gene expression compared to pretreatment OVX levels and remarkably decreased adipocyte and osteoclast-related gene expression towards pretreatment Sham levels. Late ICT treatment failed to have beneficial effect on any of these parameters.
Conclusion: ICT can exert anabolic and anti-resorptive effect on osteoporotic bone. The beneficial effect of ICT treatment is dependent on the intervention timing in established osteoporosis induced by estrogen depletion.
Copyright © 2013 Elsevier Inc. All rights reserved.
Similar articles
-
Intervention timing of strontium treatment on estrogen depletion-induced osteoporosis in rats: bone microstructure and mechanics.J Orthop Res. 2014 Mar;32(3):477-84. doi: 10.1002/jor.22517. Epub 2013 Nov 14. J Orthop Res. 2014. PMID: 24243710
-
Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats.J Bone Miner Res. 2007 Jun;22(6):849-59. doi: 10.1359/jbmr.070302. J Bone Miner Res. 2007. PMID: 17352644
-
Fast and long acting neoflavonoids dalbergin isolated from Dalbergia sissoo heartwood is osteoprotective in ovariectomized model of osteoporosis: Osteoprotective effect of Dalbergin.Biomed Pharmacother. 2016 Oct;83:942-957. doi: 10.1016/j.biopha.2016.08.010. Epub 2016 Aug 11. Biomed Pharmacother. 2016. PMID: 27522257
-
Cellular and molecular effects of growth hormone and estrogen on human bone cells.APMIS Suppl. 1997;71:1-30. APMIS Suppl. 1997. PMID: 9357492 Review.
-
[A Novel Oral Anti-osteoporosis Drug with Osteogenesis-promoting Effects via Osteoblast Differentiation].Yakugaku Zasshi. 2019;139(1):19-25. doi: 10.1248/yakushi.18-00154-2. Yakugaku Zasshi. 2019. PMID: 30606923 Review. Japanese.
Cited by
-
Antiosteoporosis Effects, Pharmacokinetics, and Drug Delivery Systems of Icaritin: Advances and Prospects.Pharmaceuticals (Basel). 2022 Mar 24;15(4):397. doi: 10.3390/ph15040397. Pharmaceuticals (Basel). 2022. PMID: 35455393 Free PMC article. Review.
-
Bisphosphonate-enoxacin inhibit osteoclast formation and function by abrogating RANKL-induced JNK signalling pathways during osteoporosis treatment.J Cell Mol Med. 2021 Nov;25(21):10126-10139. doi: 10.1111/jcmm.16949. Epub 2021 Oct 15. J Cell Mol Med. 2021. PMID: 34651433 Free PMC article.
-
The antiosteoporotic activity of central-icaritin (CIT) on bone metabolism of ovariectomized rats.Molecules. 2014 Nov 14;19(11):18690-704. doi: 10.3390/molecules191118690. Molecules. 2014. PMID: 25405287 Free PMC article.
-
CircRNA_28313/miR-195a/CSF1 axis modulates osteoclast differentiation to affect OVX-induced bone absorption in mice.RNA Biol. 2019 Sep;16(9):1249-1262. doi: 10.1080/15476286.2019.1624470. Epub 2019 Jun 19. RNA Biol. 2019. PMID: 31204558 Free PMC article.
-
Total Flavonoids of Drynariae Rhizoma Prevent Bone Loss Induced by Hindlimb Unloading in Rats.Molecules. 2017 Jun 22;22(7):1033. doi: 10.3390/molecules22071033. Molecules. 2017. PMID: 28640230 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical